期刊文献+

Lovastatin changes activities of lactate dehydrogenase A and B genes in rat myocardial cells 被引量:4

Lovastatin changes activities of lactate dehydrogenase A and B genes in rat myocardial cells
原文传递
导出
摘要 Background Lactate dehydrogenase (LDH) is a crucial regulator of energy metabolism in many organs including the heart. Lovastatin is widely used in prevention and treatment of coronary heart disease and is a drug with substantial metabolic influences. Our study aimed to determine the activities of the lactate dehydrogenase A and B (LDHA and LDHB)genes following lovastatin treatment.Methods The rat myocardial cell line H9c2(2-1) in culture was exposed to 100 nmol/L lovastatin for 24 hours or for five days. The functions of the LDHA and LDHB genes were examined at the transcriptional (mRNA) level with quantitative real-time polymerase chain reaction (Q-RT-PCR), and at the translational (protein) level with immunoblotting.Results When compared with control levels, the LDHA mRNA went up by (151.65±16.72)% (P=0.0132) after 24 hours and by (175.28±56.54)% (P=0.0366) after five days of lovastatin treatment. Although 24 hours of lovastatin treatment had no significant effects on LDHB mRNA levels, when the treatment was extended to five days, LDHB mRNA levels were significantly down-regulated to (63.65±15.21)% of control levels (P=0.0117). After 24 hours of treatment with lovastatin,there were no significant changes in protein levels of either LDHA or LDHB. When treatment time was extended to five days, the protein levels of LDHA were up-regulated by (148.65±11.81)% (P=0.00969), while the protein levels of LDHB were down-regulated to (64.91±5.47)% of control levels (P=0.0192).Conclusions Lovastatin affects gene activities of LDHA and LDHB differently, which may reveal novel pharmacological effects of lovastatin. Background Lactate dehydrogenase (LDH) is a crucial regulator of energy metabolism in many organs including the heart. Lovastatin is widely used in prevention and treatment of coronary heart disease and is a drug with substantial metabolic influences. Our study aimed to determine the activities of the lactate dehydrogenase A and B (LDHA and LDHB)genes following lovastatin treatment.Methods The rat myocardial cell line H9c2(2-1) in culture was exposed to 100 nmol/L lovastatin for 24 hours or for five days. The functions of the LDHA and LDHB genes were examined at the transcriptional (mRNA) level with quantitative real-time polymerase chain reaction (Q-RT-PCR), and at the translational (protein) level with immunoblotting.Results When compared with control levels, the LDHA mRNA went up by (151.65±16.72)% (P=0.0132) after 24 hours and by (175.28±56.54)% (P=0.0366) after five days of lovastatin treatment. Although 24 hours of lovastatin treatment had no significant effects on LDHB mRNA levels, when the treatment was extended to five days, LDHB mRNA levels were significantly down-regulated to (63.65±15.21)% of control levels (P=0.0117). After 24 hours of treatment with lovastatin,there were no significant changes in protein levels of either LDHA or LDHB. When treatment time was extended to five days, the protein levels of LDHA were up-regulated by (148.65±11.81)% (P=0.00969), while the protein levels of LDHB were down-regulated to (64.91±5.47)% of control levels (P=0.0192).Conclusions Lovastatin affects gene activities of LDHA and LDHB differently, which may reveal novel pharmacological effects of lovastatin.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第3期423-428,共6页 中华医学杂志(英文版)
关键词 LOVASTATIN lactate dehydrogenase coronary heart disease gene METABOLISM lovastatin lactate dehydrogenase coronary heart disease gene metabolism
  • 相关文献

参考文献1

二级参考文献25

  • 1Libby P.Atherosclerosis:disease biology affecting the coronary vasculature.Am J Cardiol 2006; 98:3Q-9Q.
  • 2Ijem J,Granlie C.More than cholesterol:the complexity of coronary artery disease.S D J Med 2000; 53:489-491.
  • 3Libby P.Inflammation and cardiovascular disease mechanisms.Am J Clin Nutr 2006; 83:456S-460S.
  • 4Fearon WF,Fearon DT.Inflammation and cardiovascular disease:role of the interleukin-1 receptor antagonist.Circulation 2008; 117:2577-2579.
  • 5Rana JS,Nieuwdorp M,Jukema JW,Kastelein JJ.Cardiovascular metabolic syndrome-an interplay of,obesity,inflammation,diabetes and coronary heart disease.Diabetes Obes Metab 2007; 9:218-232.
  • 6Lesperance F,Frasure-Smith N.Depression in patients with cardiac disease:a practical review.J Psychosom Res 2000; 48:379-391.
  • 7Dominiczak MH.Deteriorating fuel metabolism,inflammation and coronary disease:are we closer to an all-encompassing theory? Curr Opin Lipidol 2003; 14:639-642.
  • 8Shively CA,Musselman DL,Willard SL.Stress,depression,and coronary artery disease:modeling comorbidity in female primates.Neurosci Biobehav Rev 2009; 33:133-144.
  • 9Shively CA,Register TC,Clarkson TB.Social stress,visceral obesity,and coronary artery atherosclerosis:product of a primate adaptation.Am J Primatol 2009; 71:742-751.
  • 10Gillespie CF,Nemeroff CB.Hypercortisolemia and depression.Psychosom Med 2005; 67 Suppl 1:S26-S28.

共引文献4

同被引文献9

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部